195 related articles for article (PubMed ID: 29437160)
1. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes.
Browning MG; Khoraki J; DeAntonio JH; Mazzini G; Mangino MJ; Siddiqui MS; Wolfe LG; Campos GM
Int J Obes (Lond); 2018 Apr; 42(4):926-929. PubMed ID: 29437160
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
[TBL] [Abstract][Full Text] [Related]
3. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
5. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.
Kim D; Kim W; Adejumo AC; Cholankeril G; Tighe SP; Wong RJ; Gonzalez SA; Harrison SA; Younossi ZM; Ahmed A
Hepatol Int; 2019 Mar; 13(2):205-213. PubMed ID: 30694445
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
7. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
8. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
9. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients.
Kallwitz ER; Guzman G; TenCate V; Vitello J; Layden-Almer J; Berkes J; Patel R; Layden TJ; Cotler SJ
Am J Gastroenterol; 2009 Jan; 104(1):64-9. PubMed ID: 19098851
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.
Bril F; Portillo-Sanchez P; Liu IC; Kalavalapalli S; Dayton K; Cusi K
Diabetes Care; 2018 Jan; 41(1):187-192. PubMed ID: 29133343
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
Theel W; Boxma-de Klerk BM; Dirksmeier-Harinck F; van Rossum EFC; Kanhai DA; Apers J; van Dalen BM; de Knegt RJ; Holleboom AG; Tushuizen ME; Grobbee DE; Wiebolt J; Castro Cabezas M
Obes Rev; 2022 Aug; 23(8):e13481. PubMed ID: 35692179
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
15. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
Qureshi K; Abrams GA
Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
[TBL] [Abstract][Full Text] [Related]
17. What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?
Machado MV; Policarpo S; Coutinho J; Carvalhana S; Leitão J; Carvalho A; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Cortez-Pinto H
Obes Surg; 2020 Feb; 30(2):560-568. PubMed ID: 31637670
[TBL] [Abstract][Full Text] [Related]
18. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
León-Mimila P; Villamil-Ramírez H; Li XS; Shih DM; Hui ST; Ocampo-Medina E; López-Contreras B; Morán-Ramos S; Olivares-Arevalo M; Grandini-Rosales P; Macías-Kauffer L; González-González I; Hernández-Pando R; Gómez-Pérez F; Campos-Pérez F; Aguilar-Salinas C; Larrieta-Carrasco E; Villarreal-Molina T; Wang Z; Lusis AJ; Hazen SL; Huertas-Vazquez A; Canizales-Quinteros S
Diabetes Metab; 2021 Mar; 47(2):101183. PubMed ID: 32791310
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.
de Vries M; El-Morabit F; van Erpecum KJ; Westerink J; Bac ST; Kaasjager HAHK; de Valk HW
Eur J Intern Med; 2022 Jun; 100():77-82. PubMed ID: 35387749
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
